Arcadia Biosciences Expands GoodWheat™ Portfolio with Reduced Gluten Wheat
April 17 2018 - 8:00AM
Business Wire
-- New wheat variety demonstrates
significant reductions in allergenic glutens while maintaining
glutens important for baking --
Arcadia Biosciences (Nasdaq: RKDA), an agricultural food
ingredient company, today announced plans to add its new reduced
gluten (RG) wheat lines to its GoodWheat™ portfolio of branded
ingredients. The company expects to have its first RG bread wheat
flour available for commercial testing by the end of the year.
Arcadia’s reduced gluten wheat, developed through research
funded in part by a grant from the U.S. National Institutes of
Health’s Diabetes and Digestive and Kidney Disorders Institute, is
the second product to be added to Arcadia’s recently announced
GoodWheat™ branded ingredients platform, along with its high fiber
Resistant Starch (RS) wheat lines. The goal of the GoodWheat™ brand
is to add value to the entire wheat supply chain, from seed to
table, by enabling a wider range of choices to meet evolving
consumer demands.
Arcadia developed RG GoodWheat™ for people who enjoy the taste,
texture and nutritional benefits of wheat in the foods they love
and, at the same time, would like to reduce gluten in
their diets. The gluten-free food market is estimated to grow to
$7.59 billion by 2020 in the United States. However, only about 1
percent of the population suffers from celiac disease, which
necessitates a gluten-free diet. A much larger number of people who
choose to eat gluten-free products do not have gluten-related
medical conditions but report feeling better by consuming less
gluten.
Arcadia’s RG product is a non-GM, patent-pending, identity
preserved specialty wheat in which allergenic glutens have been
reduced by 75 percent and overall gluten content has been reduced
by 60 percent. At the same time, the levels of glutens important
for bread-making are not changed.
“A growing number of consumers are making a conscious effort to
reduce gluten in their diets, even if they haven’t been diagnosed
with celiac disease, so we developed Reduced Gluten GoodWheat™ to
give those consumers more choices to continue enjoying the healthy
wheat-based foods they love,” said Raj Ketkar, president and
CEO of Arcadia Biosciences. “These proprietary wheat
varieties, developed using advanced screening and plant breeding
techniques, also give food processors an opportunity to
differentiate their brands and create unique brand extensions.”
Arcadia expects to have its first RG GoodWheat™ branded bread
wheat flour available to test milling and baking ability in late
2018, with a projected launch for pre-commercial activities
approximately 12 months later. Development work is also ongoing as
Arcadia conducts studies into reducing allergenic gluten levels in
pasta wheat.
About Arcadia Biosciences, Inc.
Arcadia Biosciences (Nasdaq: RKDA) develops and markets
high-value food ingredients and nutritional oils that help meet
consumer demand for a healthier diet. Arcadia’s GoodWheat™ branded
ingredients deliver health benefits to consumers and enable
consumer packaged goods companies to differentiate their brands in
the marketplace. The company’s portfolio of agricultural traits are
being developed to enable farmers around the world to be more
productive and minimize the impact of agriculture on the
environment. For more information visit www.arcadiabio.com.
Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995, including statements relating to the company’s expectations
regarding when commercial testing and pre-commercial activities
will begin for its reduced gluten bread wheat flour.
Forward-looking statements are subject to risks and uncertainties
that could cause actual results to differ materially, and reported
results should not be considered as an indication of future
performance. These risks and uncertainties include, but are not
limited to: the company’s and its partners’ and affiliates’ ability
to identify and isolate desired traits; the company’s and its
partners’ ability to develop commercial products incorporating its
traits and complete the regulatory review process for such
products; the company’s compliance with laws and regulations that
impact the company’s business, and changes to such laws and
regulations; the company’s future capital requirements and ability
to satisfy its capital needs; and the other risks set forth in the
company’s filings with the Securities and Exchange Commission from
time to time, including the risks set forth in the company’s Annual
Report on Form 10-K for the year ended December 31, 2017. These
forward-looking statements speak only as of the date hereof, and
Arcadia Biosciences, Inc. disclaims any obligation to update these
forward-looking statements.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20180417005524/en/
Arcadia BiosciencesJeff
Bergau+1-312-217-0419jeff.bergau@arcadiabio.com
Arcadia Biosciences (NASDAQ:RKDA)
Historical Stock Chart
From Aug 2024 to Sep 2024
Arcadia Biosciences (NASDAQ:RKDA)
Historical Stock Chart
From Sep 2023 to Sep 2024